DICER1 tumor-predisposition syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:284343OMIM:601200C34.8
Who is this for?
Show terms as
3Active trials2Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

DICER1 tumor-predisposition syndrome (also called DICER1 syndrome) is a rare inherited condition that increases a person's risk of developing certain types of tumors, both cancerous and non-cancerous, throughout their lifetime. The condition is caused by changes (mutations) in the DICER1 gene, which normally helps control cell growth. When this gene does not work properly, cells can grow in an uncontrolled way, leading to tumors in various parts of the body. The most well-known tumor linked to this syndrome is pleuropulmonary blastoma (PPB), a rare lung tumor that typically appears in young children. Other associated tumors include cystic nephroma (a kidney tumor), ovarian Sertoli-Leydig cell tumors, multinodular goiter and thyroid cancer, nasal tumors (nasal chondromesenchymal hamartoma), pineoblastoma (a brain tumor), and other rare growths. Not everyone with a DICER1 mutation will develop tumors, and the types and timing of tumors can vary widely even within the same family. Treatment depends on which tumors develop and may include surgery, chemotherapy, or other cancer-directed therapies. Regular surveillance through imaging and physical exams is a key part of managing this condition, as early detection of tumors greatly improves outcomes. Genetic counseling is strongly recommended for affected families to understand risks and plan appropriate screening.

Also known as:

Key symptoms:

Lung cysts or lung tumors in young children (pleuropulmonary blastoma)Kidney cysts or kidney tumors (cystic nephroma)Ovarian tumors, especially in teenage girls or young womenEnlarged thyroid or thyroid nodules (multinodular goiter)Thyroid cancerNasal or sinus tumors causing breathing difficultyBrain tumor (pineoblastoma) causing headaches or vision changesEye tumor (ciliary body medulloepithelioma)Uterine tumors (embryonal rhabdomyosarcoma of the cervix)Unexplained cough or breathing problems in a young childAbdominal swelling or pain from kidney or ovarian tumorsEarly puberty signs from hormone-producing ovarian tumorsRecurrent or unusual tumors at a young age

Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

3 events
Mar 2025Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Children's Oncology Group — PHASE3

TrialRECRUITING
Feb 2011DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

National Cancer Institute (NCI)

TrialRECRUITING
Dec 2009International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry

Children's Hospitals and Clinics of Minnesota — NA

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for DICER1 tumor-predisposition syndrome.

3 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

3 recruitingView all trials with filters →
Phase 31 trial
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Phase 3
Actively Recruiting
PI: Kris Ann P Schultz (Children's Oncology Group) · Sites: Birmingham, Alabama; Phoenix, Arizona +74 more · Age: 021 yrs
N/A1 trial
International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry
N/A
Active
PI: Kris Ann P Schultz, MD (Children's Hospitals and Clinics of Minnesota) · Sites: Minneapolis, Minnesota · Age: 021 yrs
Other1 trial
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study
Actively Recruiting
PI: Douglas R Stewart, M.D. (National Cancer Institute (NCI)) · Sites: Bethesda, Maryland; Rockville, Maryland · Age: 099 yrs

Specialists

2 foundView all specialists →
DM
Douglas R Stewart, M.D.
Bethesda, Maryland
Specialist

Rare Disease Specialist

PI on 5 active trials
KM
Kim E. Nichols, MD
Memphis, Tennessee
Specialist

Rare Disease Specialist

PI on 2 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to DICER1 tumor-predisposition syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open DICER1 tumor-predisposition syndromeForum →

No community posts yet. Be the first to share your experience with DICER1 tumor-predisposition syndrome.

Start the conversation →

Latest news about DICER1 tumor-predisposition syndrome

Disease timeline:

New recruiting trial: Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

A new clinical trial is recruiting patients for DICER1 tumor-predisposition syndrome

New recruiting trial: DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

A new clinical trial is recruiting patients for DICER1 tumor-predisposition syndrome

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What specific surveillance schedule do you recommend for my child or me based on age and tumor risk?,Which family members should be tested for the DICER1 mutation?,What symptoms should I watch for between screening appointments?,Are there any clinical trials or research studies we should consider?,How will this diagnosis affect future family planning, and is prenatal testing available?,What mental health or support resources are available for our family?,At what age can surveillance be reduced or stopped?

Common questions about DICER1 tumor-predisposition syndrome

What is DICER1 tumor-predisposition syndrome?

DICER1 tumor-predisposition syndrome (also called DICER1 syndrome) is a rare inherited condition that increases a person's risk of developing certain types of tumors, both cancerous and non-cancerous, throughout their lifetime. The condition is caused by changes (mutations) in the DICER1 gene, which normally helps control cell growth. When this gene does not work properly, cells can grow in an uncontrolled way, leading to tumors in various parts of the body. The most well-known tumor linked to this syndrome is pleuropulmonary blastoma (PPB), a rare lung tumor that typically appears in young c

How is DICER1 tumor-predisposition syndrome inherited?

DICER1 tumor-predisposition syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for DICER1 tumor-predisposition syndrome?

Yes — 3 recruiting clinical trials are currently listed for DICER1 tumor-predisposition syndrome on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat DICER1 tumor-predisposition syndrome?

2 specialists and care centers treating DICER1 tumor-predisposition syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.